Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Neurontin Neuropathic Pain NDA Planned; Relpax Awaits New Study

Executive Summary

Pfizer is preparing an NDA supplement for Neurontin that could allow open marketing of gabapentin for neuropathic pain indications.

You may also be interested in...



Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

Pfizer/Pharmacia Merger: Tidbits From The SEC Filings

COX-2 co-marketing amendment: Pfizer would gain majority control over Pfizer/Pharmacia COX-2 co-marketing executive committee should Pharmacia terminate the merger agreement under certain conditions, Pfizer's Aug. 14 S-4 merger filing with the Securities & Exchange Commission states. Pfizer would name three members to the five-person committee should Pharmacia end the deal; Pfizer is currently represented by two members. The company would also be able to appoint a chairperson to "any or all" of the six subcommittees of the executive committee under the amended agreement. The merger breakup fee is $1.6 bil...

Related Content

UsernamePublicRestriction

Register

PS037071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel